MedTrace Logo

A Phase 2 Study Of PF-00232798 In HIV Positive Patients

NCT00495677 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 43

Last updated 2013-10-30

Study results available
· View outcomes & findings →

Summary

To assess the viral load response, safety, tolerability and pharmacokinetics of multiple oral doses of PF 00232798 in HIV-positive patient volunteers.

Conditions

Interventions

DRUG

PF-00232798

Solution, 20 mg. once daily, 10 days

DRUG

PF-00232798

Solution, 150 mg. once daily, 10 days

DRUG

PF-00232798

Solution, 5 mg. once daily, 10 days

DRUG

PF-00232798

Solution, 40 mg. once daily, 10 days

DRUG

PF-00232798

Solution, 300 mg. once daily, 10 days

DRUG

PF-00232798

Solution, 400 mg. once daily, 10 days

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-06-30
Primary Completion
2008-09-30
Completion
2008-09-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00495677 on ClinicalTrials.gov